XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
  Mental Health
   Depression
  Aging
  Events
  Parenting
  Fitness
  Food & Nutrition
  Happiness
  Sleep Hygiene
  Occupational Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Depression Channel
subscribe to Depression newsletter

Medical News : Health : Mental Health : Depression

   DISCUSS   |   EMAIL   |   PRINT
Drug approval processes may have delayed warnings about safety of Paroxetine
Jul 10, 2006 - 7:24:00 AM, Reviewed by: Dr. Himanshu Tyagi

�The regulators seem stuck in a world where balancing evidence of potential benefit against actual risk causes real problems,�

 
Drug approval processes may have delayed warnings about the safety of antidepressants, argues a senior doctor in this week�s BMJ.

Following GlaxoSmithKline�s recent letter to doctors pointing to a sixfold increase in the risk of suicidal behaviour in adults taking paroxetine, Professor David Healy examines the regulation of selective serotonin reuptake inhibitors (SSRIs) and asks were mistakes made and could they have been avoided?

In February 1990 an article raised concerns that the recently licensed fluoxetine might trigger suicide acts in depressed patients. Subsequent trials showed a doubling of rates of suicidal acts between active treatment and placebo, but it was only in a recent study reviewing over 700 trials that this difference became significant.

This trend should have been seen by both companies and regulators as something that required investigation, writes the author.

Trials in children conducted from the mid-1990s also show a doubling of the risks of suicidal acts with SSRIs. These results have recently formed the basis of warnings about the use of SSRIs in children. Trials in adults show a similar risk ratio yet, until May 2006, no warnings were issued for adults.

�Although data submitted to the FDA show an excess of suicides with every antidepressant licensed since 1987 compared with placebo, this simple but crucial finding continues to be obscured,� he says.

He also examines the way in which the data were presented to regulators by manufacturers, and suggests that inappropriate inclusion of suicidal acts in the placebo group biased estimates of suicide risk. Subsequent �rigid interpretation� of these data by the regulators �may have delayed warnings of dangers of suicidal acts,� he adds.

Having re-analysed the evidence, he suggests that the best estimate for the likely risk of suicide on SSRIs over placebo is 2.6 (more than double the risk) and he calls for suitably powered studies to settle the issue.

He also believes that greater data transparency and statistical sophistication might lead to earlier research to discriminate between those who do well on new drugs and those who do not.

�The regulators seem stuck in a world where balancing evidence of potential benefit against actual risk causes real problems,� he writes. �The SSRI and rofecoxib disasters have harmed public confidence in drugs. We urgently need to learn how to regulate both the risks and benefits of new treatments more effectively.�

BMJ Editor, Fiona Godlee also touches on this issue in her Editor's choice column. She talks of "an overpowerful under-regulated drug industry and a research establishment and publishing industry in its thrall." A radical solution would be to stop allowing drug companies to evaluate their own products. Is this feasible? Is it the answer? she asks.
 

- British Medical Journal
 

Read Source Article at bmj.com

 
Subscribe to Depression Newsletter
E-mail Address:

 



Related Depression News

Drug approval processes may have delayed warnings about safety of Paroxetine
Living in the past indicates dissatisfaction with present
So young, so sad, so listen - Relaunched
Royal College of Psychiatrists welcomes nice guidelines and MHRA advice on prescribing of SSRI medication in adults
Internet therapy for depression
SSRI "addiction is a myth"


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us